PAPER Ritchie CW, Ritchie K
SEARCH RESULTS
330883 RESULTS
PAPER Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, Miyazawa T
Amyloid β levels in human red blood cells.
PLoS One. 2012;7(11):e49620. PubMed: 23166730PAPER Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, Windhorst AD, Handels RL, Wolfs CA, Aalten P, Verhey FR, Verbeek MM, van Buchem MA, Hoekstra OS, Lammertsma AA, Scheltens P, van Berckel BN
Impact of molecular imaging on the diagnostic process in a memory clinic.
Alzheimers Dement. 2012 Nov 16; PubMed: 23164552PAPER Kingwell K
Alzheimer disease: New insights into preclinical Alzheimer disease.
Nat Rev Neurol. 2013 Jan;9(1):4. PubMed: 23165336PAPER Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA,
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.
J Nucl Med. 2013 Jan;54(1):70-7. PubMed: 23166389Hongna Yang
United States
Michael Wolfe on Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease.
COMMENT These cognitive effects, along with the adverse events in the gastrointestinal tract and skin, are troubling, as they are similar to the outcomes Lilly had with semagacestat. It's not the end of γ-secretase as a target, but it says that, first and fo
Hugo Geerts on Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease.
COMMENT My humble opinion is that this is a red flag for pure γ-secretase inhibitors (GSIs). The trend for worsening cognition was also seen with the Lilly GSI semagacestat. Even when taking into account the much more selective property of avagacestat to spare No
PAPER Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ
Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation.
Toxicol Sci. 2004 Nov;82(1):341-58. PubMed: 15319485PAPER Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, van der Brug MP, Wahlestedt C
Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation.
Nat Biotechnol. 2012 May;30(5):453-9. PubMed: 22446693PAPER Marcaurelle LA, Comer E, Dandapani S, Duvall JR, Gerard B, Kesavan S, Lee MD, Liu H, Lowe JT, Marie JC, Mulrooney CA, Pandya BA, Rowley A, Ryba TD, Suh BC, Wei J, Young DW, Akella LB, Ross NT, Zhang YL, Fass DM, Reis SA, Zhao WN, Haggarty SJ, Palmer M, Foley MA
An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors.
J Am Chem Soc. 2010 Dec 1;132(47):16962-76. PubMed: 21067169PAPER Maze I, Covington HE, Dietz DM, LaPlant Q, Renthal W, Russo SJ, Mechanic M, Mouzon E, Neve RL, Haggarty SJ, Ren Y, Sampath SC, Hurd YL, Greengard P, Tarakhovsky A, Schaefer A, Nestler EJ
Essential role of the histone methyltransferase G9a in cocaine-induced plasticity.
Science. 2010 Jan 8;327(5962):213-6. PubMed: 20056891James Cooper on CTAD: AD Treatment Might Not Lower Healthcare Costs
COMMENT The results of a model depend, of course, on the assumptions used for the variables in the model. For example, Dr. Wimo and colleagues concluded, in another model, that treatment of dementia with an ACEI was cost neutral. A truly successful disease-modify
Kenneth Augustyn
SRI InternationalAnn Arbor, United States
Clinical Trials on Alzheimer's Disease 2012
CONFERENCE COVERAGE SERIES CTAD: Turning the Ship Around Toward Early Trials CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate CTAD: Regulatory Science Gains Prominence in AD Research CTAD: Adaptive Antibody Trial to Try Bayesian Statistics CTAD: ApoE Carriers Sought for Tri
Current Filters
No filters selected